Cue Biopharma, Inc. (CUE)
Market Cap | 52.53M |
Revenue (ttm) | 7.02M |
Net Income (ttm) | -49.97M |
Shares Out | 48.64M |
EPS (ttm) | -1.07 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 566,470 |
Open | 1.040 |
Previous Close | 1.020 |
Day's Range | 1.020 - 1.130 |
52-Week Range | 0.937 - 4.890 |
Beta | 1.99 |
Analysts | Strong Buy |
Price Target | 8.00 (+640.74%) |
Earnings Date | Aug 7, 2024 |
About CUE
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside o... [Read more]
Financial Performance
In 2023, Cue Biopharma's revenue was $5.49 million, an increase of 340.96% compared to the previous year's $1.25 million. Losses were -$50.73 million, -4.30% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CUE stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 640.74% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/y/j/conf14-2417804.jpg)
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease...
![](https://cdn.snapi.dev/images/v1/g/4/conf12-2388265.jpg)
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disea...
![](https://cdn.snapi.dev/images/v1/b/e/press4-2361846.jpg)
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disea...
![](https://cdn.snapi.dev/images/v1/y/b/press6-2301340.jpg)
Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate diseas...
![](https://cdn.snapi.dev/images/v1/z/r/conf3-2168650.jpg)
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specif...
![](https://cdn.snapi.dev/images/v1/n/a/conf1-2143759.jpg)
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specif...
![](https://cdn.snapi.dev/images/v1/i/w/press19-2139426.jpg)
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023
BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specif...
![](https://cdn.snapi.dev/images/v1/w/i/press12-2079804.jpg)
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...
![](https://cdn.snapi.dev/images/v1/z/3/press17-2077662.jpg)
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...
![](https://cdn.snapi.dev/images/v1/g/v/press3-2015668.jpg)
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...
![](https://cdn.snapi.dev/images/v1/a/4/press19-1924361.jpg)
Cue Biopharma to Host Investor Call
BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...
![](https://cdn.snapi.dev/images/v1/v/9/conf1-1920472.jpg)
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...
![](https://cdn.snapi.dev/images/v1/o/n/press10-1908595.jpg)
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...
![](https://cdn.snapi.dev/images/v1/z/d/press4-1880826.jpg)
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modula...
![](https://cdn.snapi.dev/images/v1/7/e/conf15-1876736.jpg)
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modula...
![](https://cdn.snapi.dev/images/v1/v/3/press17-1833875.jpg)
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...
![](https://cdn.snapi.dev/images/v1/g/c/press20-1806809.jpg)
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...
![](https://cdn.snapi.dev/images/v1/7/h/conf1-1797688.jpg)
Cue Biopharma to Host Business Update Call and Webcast
BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...
![](https://cdn.snapi.dev/images/v1/e/v/conf10-1776630.jpg)
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...
![](https://cdn.snapi.dev/images/v1/c/c/press6-1764752.jpg)
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...
![](https://cdn.snapi.dev/images/v1/w/2/press5-1757703.jpg)
Cue Biopharma's Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...
![](https://cdn.snapi.dev/images/v1/s/d/press1-1757109.jpg)
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...
![](https://cdn.snapi.dev/images/v1/a/u/conf15-1732832.jpg)
Cue Biopharma to Present at Two February 2023 Scientific Conferences
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...
![](https://cdn.snapi.dev/images/v1/i/f/press13-1718085.jpg)
Cue Biopharma Announces Chief Medical Officer Transition
BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...
![](https://cdn.snapi.dev/images/v1/f/u/press5-1636043.jpg)
Cue Biopharma Reports Third Quarter 2022 Financial Results
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...